Are you a Health Professional? Jump over to the doctors only platform. Click Here

Intravenous Mepolizumab In Children With Eosinophilic Esophagitis

Print Friendly, PDF & Email

This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis.

Official Title

A Randomized, Double-Blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219)

Conditions

Eosinophilic Esophagitis

Study Type

Interventional

Study Design

Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Pharmacokinetics/Dynamics Study

Further Details

Primary Outcome Measures:

  • Safety and tolerability at Week 12 Pharmacokinetic parameters Proportion of subjects who achieve a reduction in peak eosinophils at Week 12 [Time Frame: 12 Weeks]

Secondary Outcome Measures:


  • Relationship between dose and clinical response assessed by change from baseline and the average during Weeks 9-12 and 20-24 Time to relapse in responders Relationship between PD (pharmacodynamics) and PK(pharmacokinetics). [Time Frame: 24 Weeks]

Study Start

August 2006

Eligibility & Criteria

  • Ages Eligible for Study: 2 Years – 17 Years
  • Genders Eligible for Study: Both

Inclusion criteria:

  • Isolated eosinophil esophagitis defined as greater than/equal to 20 eosinophils/HPF.

Exclusion criteria:

  • Current evidence of EGID (Eosinophilic Gastrointestinal Enteropathy) other than eosinophilic esophagitis.
  • Active H. pylori.
  • Current or suspected evidence of GERD (Gastroesophageal Reflux Disease) or other causes of esophagitis.
  • Current evidence or history of celiac disease, esophageal or generalized eosinophilia associated with infiltration in the esophagus (HES, allergic gastroenteritis, bacterial infection, parasitic infestations, collagen vascular disease, vasculitis, allergic drug reaction, graft-versus host disease).

Total Enrolment

72

Contact Details

  • Parkville, Victoria, 3052, Australia
  • Murdoch, Western Australia, 6150, Australia

Contact GlaxoSmithKline Australia (Please refer to this study by ClinicalTrials.gov identifier NCT00358449)


Print Friendly, PDF & Email

Dates

Posted On: 1 January, 2013
Modified On: 16 September, 2014

Tags



Created by: myVMC